jueves, 22 de julio de 2021

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma | FDA

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma | FDA

No hay comentarios:

Publicar un comentario